Oncotelic Therapeutics Expands Sapu003 Phase 1b Program with Global CRO Appointment, Signaling Shift to Multinational Development
Oncotelic Therapeutics and Sapu Nano expand the Phase 1b trial for Sapu003, appointing Global Clinical Trials to lead international execution, marking a transition from an Australia-based study to a multinational strategy.
Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano announced the expansion of the Phase 1b clinical development program for Sapu003 (Everolimus for Injection) and the appointment of Global Clinical Trials (GCT) as the lead contract research organization for international execution of Study SP-03-B101. The move follows recent regulatory approvals supporting study expansion and marks the transition of the Sapu003 program from an Australia-based clinical effort toward a broader multinational development strategy, including planned expansion into Europe.
SP-03-B101 is an open-label Phase 1b dose-escalation study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of Sapu003 in patients with advanced mTOR-sensitive solid tumors. The company said GCT has already completed key regulatory submissions ahead of schedule and initiated clinical operations, site activation and study management activities. Sapu003 is an intravenous formulation of everolimus developed using Sapu Nano’s Deciparticle™ platform, which is designed to improve drug delivery and provide more predictable systemic exposure than oral administration while supporting future global registrational studies.
The implications of this announcement are significant for Oncotelic and the broader oncology community. By expanding into Europe and leveraging a global CRO, Oncotelic aims to accelerate patient enrollment and generate robust data that could support future registration. The intravenous formulation of everolimus may offer advantages over oral administration, potentially reducing variability in drug exposure and improving therapeutic outcomes. For patients with advanced mTOR-sensitive solid tumors, this could mean access to a more reliable treatment option. The move also positions Oncotelic to compete in the global oncology market, where multinational trials are often required for regulatory approval.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company leverages its proprietary AI-enabled PDAOAI platform to support research and regulatory processes. For more information, visit the company’s newsroom at https://nnw.fm/OTLC. The full press release is available at https://nnw.fm/olX92.
This expansion underscores Oncotelic’s commitment to advancing its pipeline and could have lasting effects on the treatment landscape for mTOR-sensitive tumors. Investors and industry watchers will be keen to see how the multinational strategy unfolds in the coming months.